Biopsy Procedure (NCT07226856)

Name: Biopsy Procedure trial for Metastatic Pancreatic Adenocarcinoma (NCT07226856)
Uploaded: 2026-10-31T16:23:59.738Z
Duration: 1 min 26 s
Description: Biopsy Procedure trial for Metastatic Pancreatic Adenocarcinoma (NCT07226856). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07226856.

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma: a one-minute explainerNCT072268561 min

Biopsy Procedure trial for Metastatic Pancreatic Adenocarcinoma (NCT07226856). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly metastatic or recurrent pancreatic adenocarcinoma needing first-line treatment for advanced disease. Earlier perioperative chemotherapy must have ended at least twelve months ago. Prior checkpoint or CCR8-antibody therapy is excluded.

The idea: combine BMS-986340, nivolumab, gemcitabine and nab-paclitaxel infusions. BMS-986340 targets immune-suppressing CCR8-bearing cells; nivolumab blocks PD-1. The chemotherapy interferes with DNA production and cell division. Researchers first assess safety, then tumor responses. Blood and tumor samples are required.

This phase 2 study plans 43 patients. Tanios Bekaii-Saab leads three recruiting Mayo Clinic sites in the US.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.